| Trial | Treatments | Patients | Method |
|---|
| RALES, 1998 | spironolactone (25 to 50 mg daily) (n=822) vs. placebo (n=841) | patients with severeheart failure | Open Parallel groups Sample size: 822/841 Primary endpoint: death from any cause FU duration: 24 mo |
| Agostoni, 2005 | spironolactone 25mg/d (n=14) vs. placebo (n=15) | stable chronic heart failure patients with reduced influences lung diffusion (DLCO) | open Parallel groups Sample size: 14/15 Primary endpoint: FU duration: 6 months |
| Mottram, 2004 | spironolactone 25 mg/d (n=30) vs. placebo (n=0) | hypertensive patients with diastolic heart failure | double blind Sample size: 30/0 Primary endpoint: myocardial function FU duration: 6 months |
| Macdonald, 2004 | spironolactone 12.5-50 mg/d (n=43) vs. placebo (n=43) | patients with New York Heart Association class I-II congestive heart failure taking optimal treatment (including beta blockers) | double blind Cross over Sample size: 43/43 Primary endpoint: none FU duration: 3 months |
| Cicoira, 2004 | spironolactone (n=47) vs. control (n=46) | chronic heart failure patients | open Sample size: 47/46 Primary endpoint: ACE gene insertion/deletion polymorphism FU duration: 12 months |
| Cicoira, 2002 | spironolactone 12.5 to 50 mg/day (n=54) vs. control (n=52) | patients with chronic heart failure | open Parallel groups Sample size: 54/52 Primary endpoint: Ventricular Function and Exercise tolerance FU duration: 12 months |
| Yee, 2001 | spironolactone 50mg/d (n=28) vs. placebo (n=28) | patients with New York Heart Association class II to IV congestive heart failure | double blind Sample size: 28/28 Primary endpoint: FU duration: 4 weeks |
| Tsutamoto, 2001 | spironolactone 25 mg daily (n=20) vs. placebo (n=17) | patients with mild-to-moderate nonischemic congestive heart failure | double blind Parallel groups Sample size: 20/17 Primary endpoint: neurohumoral factors FU duration: 12 weeks |
| Bednarz, 2000 | Aldactone 200 mg i.v (n=11) vs. furosemide 20 mg i.v (n=10) | patients with NYHA class III to IV congestive heart failure | open Sample size: 11/10 Primary endpoint: FU duration: |
| Ramires, 2000 | spironolactone (n=19) vs. standard medical treatment (n=16) | patients with systolic dysfunction and NYHA class III CHF secondary to dilated or ischemic cardiomyopathy | open Parallel groups Sample size: 19/16 Primary endpoint: none FU duration: 20 weeks |
| Farquharson, 2000 | spironolactone 50 mg/d (n=10) vs. placebo (n=10) | patients with NYHA class II to III chronic heart failure on standard diuretic/ACE inhibitor therapy | double blind Sample size: 10/10 Primary endpoint: none FU duration: 4 weeks |
| MacFadyen, 1997 | spironolactone (50-100 mg/day) (n=21) vs. placebo (n=16) | patients with stable chronic heart failure | double blind Parallel groups Sample size: 21/16 Primary endpoint: none FU duration: 8 weeks |
| Barr, 1995 | spironolactone 50 to 100 mg/day, titrated to blood pressure and plasma potassium (added to an angiotensin-converting enzyme inhibitor) (n=28) vs. placebo (n=14) | patients with New York Heart Association II to III congestive heart failure | double blind Parallel groups Sample size: 28/14 Primary endpoint: none FU duration: 8 weeks |
| Han, 1994 | captopril plus spironolactone (n=19) vs. captopril alone (n=16) | patients with refractory CHF and New York Heart Association functional class IV without renal dysfunction, hypotension and hyperkalemia | open Sample size: 19/16 Primary endpoint: none FU duration: 4 weeks |
| Mauersberger, 1985 | spironolactone 50mg + furosemide 20 mg (n=22) vs. spironolactone 50mg + butizide 5mg (n=0) | patients with congestive heart failure | open Sample size: 22/0 Primary endpoint: none FU duration: |
| Dalhstrom, 1986 | intensified treatment with diuretics (furosemide- spironolactone) (n=10) vs. prenalterol 100-200 mg daily in addition to their basal treatment (n=10) | patients with severe chronic congestive heart failure (CHF) due to ischaemic heart disease treated with digitalis and diuretics | double blind Cross over Sample size: 10/10 Primary endpoint: exercise tolerance FU duration: 12 weeks |
